Why AbbVie Stock Is Jumping Today

Shares of AbbVie (NYSE: ABBV) were jumping 7.1% higher as of 11:10 a.m. ET on Friday after rising as much as 9.2% earlier in the day. The nice gain stemmed from the big drugmaker's 2024 fourth-quarter update on Friday morning.

AbbVie reported Q4 net revenue of $15.1 billion, up 5.6% and higher than the average estimate of $14.87 billion of analysts surveyed by Zacks Investment Research. The company posted a loss in Q4 of $0.02 per share based on generally accepted accounting principles (GAAP). However, it recorded adjusted diluted earnings per share (EPS) of $2.16. The average analysts' estimate was for adjusted EPS of $2.13, according to Zacks.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. See the 10 stocks »

What investors especially liked

If you're thinking AbbVie's Q4 results weren't spectacular enough to spark such a big jump, you're right. However, there was more to the story with the company's quarterly update.

What investors especially liked was AbbVie's guidance. The drugmaker expects full-year 2025 adjusted EPS of $12.12 to $12.32. The low end of that range is higher than the average full-year EPS estimate of analysts surveyed by LSEG.

AbbVie president Robert A. Michael was also upbeat. He said in the press release announcing the Q4 results, "We are entering 2025 with significant momentum and expect net revenues to exceed their previous peak in just the second full year following the U.S. Humira loss of exclusivity."

Is AbbVie stock a buy?

I think AbbVie is a fantastic stock to buy for income investors who also like some growth. The company is a Dividend King, with a high forward dividend yield of 3.5%. The stock is also reasonably valued with a forward earnings multiple of 14.6.

Don’t miss this second chance at a potentially lucrative opportunity

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

• Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $323,219!*
• Apple: if you invested $1,000 when we doubled down in 2008, you’d have $44,996!*
• Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $524,860!*

Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.

Learn more »

*Stock Advisor returns as of January 27, 2025

Keith Speights has positions in AbbVie. The Motley Fool has positions in and recommends AbbVie. The Motley Fool has a disclosure policy.